Cardiff Oncology (NASDAQ:CRDF – Get Free Report) and iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.
Institutional and Insider Ownership
16.3% of Cardiff Oncology shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 7.8% of Cardiff Oncology shares are held by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Cardiff Oncology and iTeos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cardiff Oncology | -6,594.92% | -54.54% | -47.11% |
| iTeos Therapeutics | N/A | -23.15% | -20.20% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardiff Oncology | 0 | 0 | 2 | 0 | 3.00 |
| iTeos Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
Cardiff Oncology currently has a consensus price target of $10.50, indicating a potential upside of 368.75%. iTeos Therapeutics has a consensus price target of $32.00, indicating a potential upside of 93.12%. Given Cardiff Oncology’s higher possible upside, equities analysts clearly believe Cardiff Oncology is more favorable than iTeos Therapeutics.
Risk & Volatility
Cardiff Oncology has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cardiff Oncology and iTeos Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardiff Oncology | $490,000.00 | 204.43 | -$41.44 million | ($0.90) | -2.49 |
| iTeos Therapeutics | $12.60 million | 47.50 | -$112.64 million | ($3.78) | -4.38 |
Cardiff Oncology has higher earnings, but lower revenue than iTeos Therapeutics. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
iTeos Therapeutics beats Cardiff Oncology on 7 of the 13 factors compared between the two stocks.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
About iTeos Therapeutics
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
